Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days (NAI113625)

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: September 24, 2009
Last updated: October 11, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2009
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)